The Uniform Accounting Monthly Report | August 4, 2023



Deficiencies in GAAP/IFRS vis-a-vis Uniform Accounting

The US tax code is a nightmare for taxpayers.

The process of filing every year is met with dread and resignation from businesses and individuals alike. The U.S. tax code is extremely large and complex. What's worse, even a small mistake could lead to an audit or fine from the IRS.

For context, tax statutes passed by Congress into law total about 2,652 pages and explain tax regulations in over 1 million words. By comparison, that is longer than the King James Bible, with 788,280 words, and comparable to the entire Harry Potter collection of novels.

On top of the statutes, there are many more examples of case law, IRS regulations, revenue rulings, and other clarifications needed to garner a full comprehension of US taxes.

Combined, all of these sources sum to over 70,000 pages and 32 million words. And these figures don't even consider the tax codes of other nations. With such a lengthy anthology, it's no wonder tax specialists exist, many of whom, by and large, focus on one small part of the whole tax equation.

Compared to corporations, individual taxes are a breeze. Individuals typically don't have to deal with the complexity of subsidiaries and holding structures, partial ownership and JV interests, international jurisdictions, and more. These headaches are left to the many accountants employed by the firms, who are often paid large sums in order to try to minimize these tax bills.

Unfortunately, tax codes are not just a nightmare for individual taxpayers and accountants. They also can be an important issue for investors.

In extreme cases, taxes can lead to soaring litigation costs and potentially massive bills down the line.

For instance, Apple has been locked in a near-decade long dispute with European Union regulators over the handling of tax agreements with Ireland. Slated to come to its conclusion near the end of 2023, this fight could ultimately lead to a 13-billion-euro payment, a rather material consideration for shareholders.

Presented to the UAFRS Advisory Council

Prepared by Valens Research 1(917) 284 6008

Joel Litman, CPA Chief Investment Strategist

Rob Spivey, CFADirector of Research

Angelica Lim Research Director

Aaron Karasik, CFA Senior Analyst

The Uniform Accounting Monthly Report | August 4, 2023

Deficiencies in GAAP/IFRS vis-a-vis Uniform Accounting

Beyond tax litigation and disputes, for many firms, taxes can end up being a critical component of understanding whether to invest into a firm or pass it by. This is because, as many of the top investors know, it is important to make decisions on the basis of after-tax earnings.

Since taxes are a real expense companies face, and require a cash outlay in almost every year, they are an important consideration when understanding the underlying operating fundamentals of a firm. They are essential to properly evaluate historical performance and model potential future results.

However, as-reported tax expenses can sometimes stray significantly from both conventional wisdom and operating reality.

Take the pharmaceutical company AbbVie for example.

In 2020, the firm's EBT (earnings before taxes) was \$3.4 billion. One would stand to reason the firm's earnings would decrease after deducting taxes. After all, the IRS always wants to collect its "fair share".

Assuming AbbVie paid a corporate average of 20%, an additional \$700 million would go to the government through tax payments. Therefore, the firm's earnings after tax should sit around \$2.7 billion.

However, based on reported values, this was far from the case. AbbVie reported earnings after taxes in 2020 of \$4.6 billion, about \$1.2 billion higher than its earnings before taxes and about \$2 billion higher than a reasonable estimation.

With such a deviation from expectation, it becomes difficult for investors to understand the true earnings performance of AbbVie, and even harder to extrapolate its future capacity to reward shareholders through business reinvestment and cash distributions.

In any given year, a company can take advantage of various "tax shields" present in the tax code that protect them from reporting an economically accurate "effective" tax rate and payment.

Fortunately, it is possible to adjust for the one-time distortions inherent to tax law, allowing a company to be accurately compared year to year over a lengthy time period.

The Uniform Accounting Monthly Report | August 4, 2023

Deficiencies in GAAP/IFRS vis-a-vis Uniform Accounting

Using Uniform Accounting, the benefits of these tax shields are removed from operating earnings as these one year-tax windfalls are not representative of the underlying reality of business. While there are many reasons why taxes could deviate from reasonable expectations, there are two tax shields that are encountered most regularly: net operating loss tax shields and interest expense tax shields.

The first tax shield-requiring adjustment relates to net operating losses (NOLs).

NOLs occur when a company's expenses exceed its income - the government considers the business running at a "loss" that year. Therefore, the IRS doesn't tax the company in order to help it get back on its feet. The rationale being that a company that survives will pay taxes later down the road.

However, the IRS tax code also allows companies to carry forward these NOLs into future years. A company with an especially large loss one year could pull forward this item for multiple years, claiming no tax expense the whole time. Naturally, the ability to do so is limited, and until the NOLs run out, investors would be tricked into believing that the firm is far more profitable than it is.

Under Uniform Accounting, NOL tax shield adjustments are made when a firm's effective tax rate is materially lower than the norm for the company. In essence, this adjustment helps to square up taxes to a more reasonable level - a level that is much more representative of a firm's underlying performance and expected future results.

When a firm's effective tax falls below its average tax rate and is employing NOLs, an adjustment is made to add back the impact of this NOL on calculating the real operating tax burden of the firm. Hence, the artificial "boost" from NOLs is removed from the year in question.

The second common tax shield-requiring adjustment is related to interest expenses.

Interest payments on debt are considered a tax-deductible expense per tax code - therefore, taking on debt creates a tax shield. This can lead to companies increasing their leverage and interest payments to take advantage of the associated tax benefit. As such, highly leveraged firms can look far more tax efficient than is accurate.

The Uniform Accounting Monthly Report | August 4, 2023

Deficiencies in GAAP/IFRS vis-a-vis Uniform Accounting

That said, at its heart, leverage and interest is not an operating consideration, it's a financing decision. As such, their impact should not be considered in the analysis of a firm's operating after-tax earnings. It should instead be considered in the analysis of capital structure and capital allocation.

So for the same reason Uniform Accounting adds back interest expense to operating earnings, the "extra" tax benefit from interest is removed.

Ultimately, the tax adjustments inherent to Uniform Accounting derive a cleaner operational picture.

Looking back at AbbVie, both tax shield adjustments affect the firm, and have continued to severely distort the company's tax burden and operating earnings. When adjusting for the billions of NOLs employed in 2020, as well as the \$2.4 billion interest expense the firm faced that year, the firm's \$1.2 billion tax benefit becomes a \$600 million tax charge, much closer to reasonable expectations and far more indicative of long-run operating realities.

This higher tax expense makes sense from a logical point of view. Higher taxes should correlate with better performance, and not vice versa as permissible in as-reported figures.

Financial statement users, and investors in particular, have a key incentive to understand the core expenses affecting a company. Understanding underlying operating performance can lead to critical decisions with potential for alpha generation.

Through the adjustments made to taxes under Uniform Accounting, investors can understand a company's true tax burden without major distortions, allowing them to make more informed investment decisions.

As a result, taxes become far less of a nightmare when analyzing companies, and only a nightmare when personal ones are due.

The report name "Clay Tokens" comes from the earliest known form of accounting and bookkeeping and a foundation for tracking the earliest debits and credits. In this regard, Uniform Accounting is an attempt to get financial statements back to the foundations of the purpose of accounting... to be useful to the users of the accounting information. Clay Tokens is produced monthly by Valens Research on behalf of and for the UAFRS Advisory Council for Uniform Adjusted Financial Reporting Standards.

The Uniform Accounting Monthly Report | August 4, 2023

Deficiencies in GAAP/IFRS vis-a-vis Uniform Accounting

Disclaimer

© 2023 (Valens Research LLC, Valens Credit LLC, Valens Securities, Equity Analysis & Strategy and Altimetry Research and/or its licensors, predecessors, successors, parents, subsidiaries, affiliates, officers, directors, shareholders, investors, employees, agents, representatives, products ((including but not limited to FA Alpha, FA Alpha Academy and FA Alpha brand)) and attorneys and their respective heirs, successors, and assigns hereinafter referred to as the "Valens").

All rights exclusively and explicitly reserved.

Credit, business, stock, equity, asset and asset allocation, income and outcome, growth, liquid, investment, spending, income, cash and cash flow or any kind of analyses issued hereby, by Valens ("Valens' Analyses"), are Valens' current opinions of the relative future credit or personal asset and asset allocation risks, business, equity and other related assets of the relevant persons, entities, credit commitments, or debt or debt-like securities, credit, business and risk analyses, and research publications published or soon to be published or shared by or with in association with Valens ("Valens Publications") may include Valens' current opinions of the relative future credit or cash or asset risk of entities or persons, credit commitments, income, outcome or debt or debt-like securities, business, equity and other related assets.

Valens' Analyses and Valens Publications do not constitute or provide professional investment or financial offer or advice to any person or company. Valens' Analyses and Valens Publications are not and do not provide recommendations to purchase, sell, or hold particular securities, spend or hold personal assets and properties.

Valens accepts no liability and responsibility from any kind of damage or responsibility that may arise from any false notion, misguidance or mistake regarding the aforementioned. Valens' Analyses may not address any other risk arising either from personal or commercial investment and action.

Neither Valens' Analyses nor Valens Publications comment on the suitability of an investment or allocation for any particular person and neither Valens' Analyses nor Valens Publications under any circumstance accept any kind of liability or responsibility arising from self-misguidance of any particular person or any other 3rd parties.

Valens issues Valens' Analyses and publishes Valens Publications with the expectation and understanding that each 3rd party and each user of the information contained herein or to be issued by Valens will make their own study and evaluation, in a deliberate, cautious and prudent way, of each security that is under consideration for purchasing, holding, selling or for any transaction.

It would be dangerous for 3rd parties or any other information receivers, to make any financial or investment decision based solely on any of the Valens' ratings, Valens Publications or Valens' Analyses. It is highly recommended to contact your contracted financial, legal or other professional adviser.

All information and calculation contained herein is obtained by Valens from sources believed by it to be accurate, up to date and reliable. Because of the possibility of human or mechanical error as well as other factors, however, all information contained herein is provided "as is"; without representation of accuracy or any kind of warranty, obligation or any kind of commitment and undertaking.

Valens adopts all reasonable measures so that the information used or to be used assigning a credit, business, equity or any other rating if any, is of sufficient quality. Valens considers from its sources including, when appropriate, independent third-party sources, to be reliable.

However, Valens is not an auditor and cannot in every instance independently verify or validate information received in the rating or any other process. Under no circumstances shall Valens have any liability or responsibility to any person or entity/entities for any kind of loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance or contingency within or outside the control of Valens in connection with the procurement, collection, compilation, analysis, interpretation, communication, publication or delivery of any such information, or any direct, indirect, special, consequential, compensatory or incidental damages whatsoever (including without limitation loss of profits), even if Valens is advised in advance of the possibility of such damages, resulting from the use of or inability to use of any such information.

Any analysis, financial reporting analysis, projections, calculations, assumptions and other observations constituting part of the information contained herein are, and must be construed solely as, statements of opinion and not statements of fact or recommendations to purchase, sell or hold any securities and/or assets. Each user of the information contained herein must make their own study and evaluation, in a deliberate, cautious and prudent way, of each security considered for purchasing, holding, selling or doing any kind of transactional action whether for trade or personal purposes.

No warranty, express or implied, as to the accuracy, timeliness, completeness, merchantability or fitness for any particular purpose of any such rating or other opinion or information or calculation is given or made by Valens in any form or manner whatsoever.

All intellectual property rights in relation to Valens' Analyses and Valens Publications and any information or material contained herein are the exclusive property of Valens. Aforementioned cannot be copied, recorded by any audio or video recording device, screen capturing or screen recording device or any device capable of performing such function and cannot be reproduced or used without the mutual and prior written consent of respective right owner(s). 3rd parties cannot use Valens' Analyses or Valens Publications for advertising purposes, to solicit business or for any other purpose. Using, copying or reproducing any materials, content and information of Valens' Analyses is prohibited, unless permitted by speakers in writing. It is strictly prohibited to reproduce, record, represent, display, modify, adapt or translate Valens' Analyses or Valens Publications and/or any work and material contained herein in whole or in part, whether for free or for financial consideration, without speakers' mutual and prior written consent.

Valens' Analyses, including the attached exhibits or documents, if any, is confidential and is intended for the sole and exclusive use of the person to whom this material has been delivered by Valens. Any further distribution, divulgence or reproduction of these materials is strictly prohibited.

All information contained herein is protected by relevant law of United States of America, including but not limited to copyright law and intellectual property law and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, including but not limited to commercial or non-commercial use, in whole or in part, in any form or manner or by any means whatsoever, by any person or legal entity/entities without Valens' prior and explicit written consent and civil and criminal liability will arise in violation of the mentioned above.